3 recruiting, 2 active not recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Active not recruiting 2 |
Follow Tecartus: new trials by email Literature Review of Tecartus trials Research Report on Tecartus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL Pirtobrutinib, Brexucabtagene Autoleucel - Mantle Cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 60 | 2024-08-23 | 2026-09-23 |
| Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia KTE-X19, Cyclophosphamide, Fludarabine - Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Kite, A Gilead Company | 25 | 2024-03-18 | 2026-06-25 |
| Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) Tecartus - B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 60 | 2023-12-26 | 2026-09-25 |
| MT2017-45: CAR-T Cell Therapy for Heme Malignancies KYMRIAH, YESCARTA, Fludarabine 30mg/m2 4 doses - Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 150 | 2018-12-18 | 2026-01-23 |
Lymphoma, Mantle-Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Burkitt Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Recurrence (1)
H. Lee Moffitt Cancer Center and Research Institute (2) · Kite, A Gilead Company (1) · Masonic Cancer Center, University of Minnesota (1) · University of Michigan Rogel Cancer Center (1)
United States (4) · Japan (1)
Bijal D. Shah, MD (1) · Michael Jain, MD, PhD (1) · Monalisa Ghosh (1) · Veronika Bachanova, MD, PhD (1)